Fast track gives the President of the United States authority to negotiate trade agreements that cannot be amended by Congress, only voted on yes or no. It was in effect from 1975 to 1994 and led to the adoption of the Free Trade Agreement with Canada NAFTA. It was restored in 2002 by the U.S. Trade Promotion Authority Act.

See U.S. Trade Promotion Authority Act.

Fast track is also an FDA program that expedites development and testing for an experimental drug that treats a serious or life-threatening medical condition for which no other drug either exists or works as well. The status applies to the set of a product and the associated condition it helps. The FDA will accept partial results for fast track drugs undergoing testing to speed up an approval decision. As an example, the drug that lessens peanut allergies, TNX-901, received fast track status during its testing, even though other products exist to reduce allergic symptoms in general.